Patents Examined by Taofiq Solola
  • Targeting Mcl-1 to enhance DNA replication stress sensitivity for cancer therapy
    Patent number: 11524000
    Abstract: This disclosure relates to inhibitors of Mcl-1 stimulated homologous recombination (HR) DNA repair and uses for treating cancer. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering an inhibitor of Mcl-1 in combination with other anti-cancer agents, e.g., that induce DNA replication stress. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering compounds disclosed herein in combination with hydroxyurea, olaparib, or combinations thereof.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: December 13, 2022
    Assignee: Emory University
    Inventors: Xingming Deng, Guo Chen, Abu Syed Md Anisuzzaman
  • Benzamide compound and preparation method, use, and pharmaceutical composition thereof
    Patent number: 11518744
    Abstract: The present invention relates to a benzamide compound and a preparation method, use and pharmaceutical composition thereof. The benzamide compound represented by formula (I) is a STAT3 inhibitor, and can be used to prevent and/or treat a disease related to STAT3 activity, such as a tumor, autoimmune disease, renal disease, cardiovascular disease, inflammation, metabolic/endocrine dysfunction, and neurological disease.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: December 6, 2022
    Assignee: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Heng Xu, Xiaoguang Chen, Songwen Lin, Ming Ji, Nina Xue, Deyu Wu, Jing Jin
  • Methods of treatment for cystic fibrosis
    Patent number: 11517564
    Abstract: Compound I of the formula (I) and/or pharmaceutically acceptable salt(s) of Compound I comprised in a pharmaceutical composition and methods of using the same to treat cystic fibrosis.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: December 6, 2022
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Weichao George Chen, Eric L. Haseltine, Samuel Moskowitz, Sarah Robertson, David Waltz
  • Inhibitors of platelet function and methods for use of the same
    Patent number: 11498905
    Abstract: Disclosed herein are small molecule inhibitors of platelet function, and methods of using the small molecules to treat diseases, such as platelet hemostasis and thrombosis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: November 15, 2022
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Michael Holinstat, Reheman Adili, Andrew White, Theodore R. Holman
  • Prognosis method of multiple myeloma
    Patent number: 11499197
    Abstract: The invention relates to a method for in vitro predicting the outcome of an individual having a multiple myeloma, comprising the steps of: a. measuring the expression level of genes coding for kinases, b. calculating a score value for each genes; and c. classifying the individual as having a good or a bad outcome.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: November 15, 2022
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, UNIVERSITÉ DE MONTPELLIER
    Inventors: Jerome Moreaux, Hugues De Boussac, Alboukadel Kassambara
  • Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation
    Patent number: 11497743
    Abstract: Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: November 15, 2022
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
  • Cyclopenta[c]chromium compound and preparation method therefor
    Patent number: 11485722
    Abstract: The present invention discloses a cyclopenta[c]chromene compound and a preparation method thereof. A chalcone compound as a reactant, A cationic rare earth metal compound Ln(CH3CN)9]3+[(AlCl4)3]3?.CH3CN as a catalyst, and 2-naphthalenethiol as an accelerator, react in an organic solvent to prepare the cyclopenta[c]-chromene compound. Ln represents a positive trivalent rare earth metal ion, which is selected from the group consisting of La, Nd, Sm, Gd, and Yb. The starting materials are easy obtained, the reaction process is simple, and the yield of the target product is high, up to 85%.
    Type: Grant
    Filed: January 31, 2021
    Date of Patent: November 1, 2022
    Assignee: SOOCHOW UNIVERSITY
    Inventors: Fan Xu, Xiaoyou Ding, Dandan Li, Yanan Zhu, Zhigang Yao
  • Process for purification of tetrahydrocannabinolic- and cannabidiolic acid from plant material extract
    Patent number: 11472785
    Abstract: The present invention relates to a highly economic process for the purification of a cannabinoid acid, more specifically THCA or CBDA, from either a crude cannabis plant material or a cell culture of said cannabis plant, using ion exchange resins. The purified cannabinoid acid obtained may then be decarboxylated to yield the corresponding cannabinoid, i.e., THC or CBD, respectively.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: October 18, 2022
    Assignee: AL&AM Pharmachem Ltd.
    Inventor: Alexander Aizikovich
  • Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist
    Patent number: 11472811
    Abstract: Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as an A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as an A2A receptor antagonist.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: October 18, 2022
    Assignee: BEIGENE, LTD.
    Inventors: Guoliang Zhang, Changyou Zhou
  • Method for preparing a non-radioactive standard ?-CFT
    Patent number: 11466002
    Abstract: This invention discloses method for preparing a non-radioactive standard ?-CFT. Using cocaine hydrochloride as the starting material, and after a series of hydrolysis, dehydration, esterification and bonding reactions, a non-radioactive standard (2?-Carbomethoxy-3?-(4-fluoropenyl) tropane) is prepared. Furthermore, this preparation method has fewer steps, is easy to operate, and the purity of the product is as high as 97.97%. Therefore, the method for preparing a non-radioactive standard ?-CFT can promote the development of positron imaging in the diagnosis of Parkinson's disease.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: October 11, 2022
    Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN, R.O.C.
    Inventors: Ching Yun Lee, Yu Chang
  • Selective A2A receptor antagonist
    Patent number: 11440916
    Abstract: The present invention relates to a selective A2A receptor antagonist, and in particular to a selective A2A receptor antagonist of Formula (I), a pharmaceutical composition comprising the antagonist, use of the antagonist in manufacturing a medicament and in treatment of a disease: wherein the groups in Formula (I) are defined as in the specification.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: September 13, 2022
    Assignee: INXMED (NANJING) CO., LTD.
    Inventors: Zaiqi Wang, Lihu Yang
  • Crystalline polymorphs of Rivoceranib and Rivoceranib mesylate
    Patent number: 11434202
    Abstract: The present disclosure encompasses crystalline polymorphs of Rivoceranib and Rivoceranib mesylate (Apatinib mesylate), processes for preparation thereof, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: September 6, 2022
    Assignee: ASSIA CHEMICAL INDUSTRIES LTD.
    Inventors: Anantha Rajmohan Muthusamy, Sundara Lakshmi Kanniah, Elluru Subbireddy
  • Methods and agents for treating disease
    Patent number: 11434234
    Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving elevated levels of aldosterone or abnormal or excessive fibrosis, such as kidney disease and hypertension.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: September 6, 2022
    Assignee: Angion Biomedica Corp.
    Inventors: Bijoy Panicker, Lambertus J. W. M. Oehlen
  • Spiro-lactam NMDA modulators and methods of using same
    Patent number: 11427585
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: August 30, 2022
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Dihydrooxadiazinones
    Patent number: 11427553
    Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: August 30, 2022
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Manuel Ellermann, Stefan Nikolaus Gradl, Charlotte Christine Kopitz, Martin Lange, Adrian Tersteegen, Philip Lienau, Christa Hegele-Hartung, Detlev Sülzle, Timothy A. Lewis, Heidi Greulich, Xiaoyun Wu, Matthew Meyerson, Alex Burgin
  • Aryl receptor modulators and methods of making and using the same
    Patent number: 11427600
    Abstract: The present invention is generally directed towards compounds capable of binding the aryl hydrocarbon receptor and modulating its activity, methods of treating inflammatory conditions such as Crohn's disease using such compounds, and pharmaceutical compositions comprising such compounds. Also provided are methods of increasing levels of IL-22 in a subject and/or decreasing levels of IFN-? in a subject.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: August 30, 2022
    Assignee: Nogra Pharma Limited
    Inventors: Francesca Viti, Salvatore Bellinvia, Salvatore Demartis
  • SHP2 inhibitors and methods of use thereof
    Patent number: 11426422
    Abstract: Provided are methods for the treatment of insulin resistance and insulin receptor diseases with SHP2 inhibitors, such as allosteric inhibitors of SHP2 and RNAi or siRNA that target SHP2 expression. Compositions and methods for delivery of SHP2 inhibitors, such as liver-targeting liposomes or nanoparticles, are also provided.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: August 30, 2022
    Assignee: Research Development Foundation
    Inventors: Hongtao Yu, Eunhee Choi
  • Intermittent dosing of MDM2 inhibitor
    Patent number: 11419870
    Abstract: The present disclosure relates to mdm2 inhibitors for use in specific dosing schedules. It was found that if sufficiently potent or, in alternative, sufficiently high dose of a Mdm2 inhibitor is used, it can cause antineoplastic effect by triggering much longer lasting antiproliferative mechanism in cells. The long lasting effect can sustain for several weeks after a single dose, which eliminates the need for daily treatment and allows administering the Mdm2i intermittently. A treatment with the intermittent dosing schedule of a Mdm2 inhibitor can be combined with a daily treatment of the Mdm2i or with another pharmaceutically acceptable ingredient.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: August 23, 2022
    Assignee: Novartis AG
    Inventors: Stephane Ferretti, Sebastien Jeay
  • Active-energy-ray-polymerizable initiator, active-energy-ray-polymerizable composition, active-energy-ray-polymerizable ink, ink storage container, image forming method, and image forming apparatus
    Patent number: 11414557
    Abstract: An active-energy-ray-polymerizable initiator having a structure represented by the following general formula (1) is provided. In general formula (1), L1 represents —C(?O)—O— (binding to L2 side) or —O—, L2 represents —O(CH2)p-(binding to L1 side), —(OC2H4)n-(binding to L1 side), or —(OC3H6)m-(binding to L1 side), where p represents an integer of 2 to 16, n represents an integer of 2 to 12, and m represents 2 or 3, L3 represents a direct binding or —NH—, L4 represents —OC2H4-(binding to L3 side) or —(OC2H4)2-(binding to L3 side), and R represents —H or —CH3.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: August 16, 2022
    Assignee: RICOH COMPANY, LTD.
    Inventors: Shigeyuki Harada, Hidetoshi Fujii
  • Selective organic cation transporters inhibitors for the treatment of depressive disorders
    Patent number: 11414398
    Abstract: Disclosed are organic cation transporters (OCTs) inhibitors of Formula (A), as well as their pharmaceutically acceptable tautomers, salts or solvates. Also disclosed are pharmaceutical compositions including such OCTs inhibitor of Formula (A) and their use for treating and/or preventing mood-related disorders such as depressive disorders.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: August 16, 2022
    Assignees: SORBONNE UNIVERSITÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ PARIS CITÉ
    Inventors: Sophie Gautron, Nicolas Pietrancosta, Francine Acher, Laetitia Chausset-Boissarie